Related Experiment Video
Updated: May 19, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
The out-of-focus bias in drug surveillance
Markus Gnädinger1, Hans-Ulrich Mellinghoff
1Department of General Practice, University Hospital Zurich, Zurich, Switzerland. markus.gnaedinger@hin.ch
Purpose:
Existing drug safety systems with phase II and III studies and post-marketing surveillance by principle do not allow for the recognition of an important class of adverse drug reactions (ADRs). ADRs that are resistant to being detected reliably may a) appear as if they are age-related chronic diseases, which also manifest themselves in a high degree without drug treatment, b) arise in "old" drugs, c) arise during long-term application, and d) arise with the administration to frail and aged populations.
Conclusions:
"Silent" and multi-factorial health problems evolving from long-term drug treatment must therefore be addressed with a systematic search strategy, as a third track along with the phase II and III studies and spontaneous reporting systems which still exist.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Therapeutic Drug Monitoring: Affecting Factors
Drug Concentrations: Measurements
Plasma —...
Drug Regulation
Dose-Response Relationship: Selectivity and Specificity
Drug Control Governance: Regulatory Bodies and Their Impact

